Results 11 to 20 of about 5,368,097 (298)

Alzheimer disease [PDF]

open access: yesNature Reviews Disease Primers, 2021
Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic neurodegenerative disease that causes an amnestic cognitive impairment in its prototypical presentation and non-amnestic cognitive impairment in its less common variants.
David S. Knopman   +7 more
openaire   +4 more sources

Alzheimer’s disease [PDF]

open access: yesCurrent Biology, 2018
The German psychiatrist and neuropathologist Alois Alzheimer was fascinated by the symptoms of Auguste D., a 50-year-old woman admitted to the Frankfurt Psychiatric Hospital in 1901 who suffered from memory disturbances, paranoia and progressive confusion. After her death and autopsy, Alzheimer described histological alterations in her brain that later
Grøntvedt, G.   +5 more
openaire   +5 more sources

Alzheimer’s disease [PDF]

open access: yesNetwork: Computation in Neural Systems, 2011
Over the last three decades, advances in biochemical pathology and human genetics have illuminated one of the most enigmatic subjects in biomedicine--neurodegeneration. Eponymic diseases of the nervous system such as Alzheimer's, Parkinson's, and Huntington's diseases that were long characterized by mechanistic ignorance have yielded striking progress ...
Adam, Gazzaley, Scott A, Small
openaire   +4 more sources

Alzheimer's disease [PDF]

open access: yesJournal of Neurology, Neurosurgery & Psychiatry, 2000
Use of valid diagnostic criteria is extremely important in the recognition of Alzheimer's disease (AD). Patients with mild to moderate Alzheimer's disease should be started on a cholinesterase inhibitor and possibly anti-inflammatory agents, antioxidants (vitamin E or selegiline), and estrogen replacement therapy (for postmenopausal women).
, Schachter, , Davis
  +8 more sources

Angiotensin II Receptor Blockers Reduce Tau/Aß42 Ratio: A Cerebrospinal Fluid Biomarkers’ Case-Control Study

open access: yesPharmaceutics, 2023
(1) Background: The role of antihypertensives in Alzheimer’s Disease (AD) prevention is controversial. This case-control study aims to assess whether antihypertensive medication has a protective role by studying its association with amyloid and tau ...
Gemma García-Lluch   +5 more
doaj   +1 more source

TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease

open access: yesActa Neuropathologica Communications, 2018
TDP-43 pathology was investigated in the anterior temporal pole cortex (ATPC) and orbital frontal cortex (OFC), regions often degenerated in frontotemporal lobar degenerations (FTLD), in aging and Alzheimer’s disease (AD).
Sukriti Nag   +5 more
doaj   +1 more source

In-Depth Characterization of Endo-Lysosomal Aβ in Intact Neurons

open access: yesBiosensors, 2022
Amyloid-beta (Aβ) peptides are produced within neurons. Some peptides are released into the brain parenchyma, while others are retained inside the neurons. However, the detection of intracellular Aβ remains a challenge since antibodies against Aβ capture
Alec K. McKendell   +5 more
doaj   +1 more source

Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET

open access: yesActa Neuropathologica Communications, 2018
This study aimed to determine the pattern of [18F]flortaucipir uptake in individuals affected by Gerstmann-Sträussler-Scheinker disease (GSS) associated with the PRNP F198S mutation.
Shannon L. Risacher   +11 more
doaj   +1 more source

Arterial Spin-Labeling MRI at the Cortical-CSF Interface: A Novel Biomarker in Alzheimer Disease. [PDF]

open access: yesAnn Clin Transl Neurol
ABSTRACT Background/Objective Arterial spin‐labeling (ASL) MRI can measure perfusion signal adjacent to CSF spaces and may provide information regarding CSF‐adjacent water transport physiology. We developed an automated pipeline to extract cortical‐CSF interface (IF) perfusion for comparison between Alzheimer disease (AD) and cognitively normal ...
Asghariahmadabad M   +22 more
europepmc   +2 more sources

Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A

open access: yesNeurobiology of Disease, 2008
The down-regulation of protein phosphatase 2A (PP2A) activity is thought to play an important role in the formation of tau hyperphosphorylation in the Alzheimer's disease (AD) brain. Methylation of the PP2A catalytic subunit at the L309 site can potently
Xin-Wen Zhou   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy